Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06261580 · ClinicalTrials.gov registry record
Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers
A clinical trial of Healthy, sponsored by Haemonetics Corporation.
- Completed
- Registry status
- 181
- Enrollment target
- 3
- Study locations
NCT06261580: Completed study of Healthy, sponsored by Haemonetics Corporation.
NCT06261580 is a study of Healthy that has completed, run by Haemonetics Corporation. The registered enrollment target is 181 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (72% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06261580, a study of Healthy, has completed, sponsored by Haemonetics Corporation.
- COMPLETED
- Registry status
- 181 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial holds minimal risk to the trial volunteers and consists of obtaining whole blood via venipuncture to perform coagulation parameter measurements to define a Normal Reference Range. Written consent to participate in the study will be obtained prior to volunteer screening per site procedures.
Primary Outcome
Citrated Kaolin Maximum Amplitude Thromboelastographic Result
Conditions Studied
Interventions
- DIAGNOSTIC_TEST TEG 6s Citrated K, KH, RTH, and FFH Cartridge
- DIAGNOSTIC_TEST Clauss Fibrinogen
Study Locations (3)
California
- Machaon Diagnostics - Oakland
Illinois
- Cardiovascular Research Institute - Loyola University Chicago Health Sciences - Maywood
Louisiana
- Louisiana Coagulation / Machaon Division - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2021-10-25 |
What the finished NCT06261580 record still lists
NCT06261580 is an observational study that tracks outcomes without assigning an intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which TEG 6s Citrated K, KH, RTH, and FFH Cartridge is the first listed.
NCT06261580 reports a single indexed study location in California, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06261580 about?
NCT06261580 is a clinical study titled "Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers". This trial holds minimal risk to the trial volunteers and consists of obtaining whole blood via venipuncture to perform coagulation parameter measurements to define a Normal Reference Range. Written consent to participate in the study will be obtained prior to volunteer screening per site procedure...
What is the current status of trial NCT06261580?
This trial is currently completed. The enrollment target is 181 participants. The study started on 2021-07-28. Estimated completion is 2021-10-25.
What conditions does trial NCT06261580 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06261580?
The interventions under investigation include: TEG 6s Citrated K, KH, RTH, and FFH Cartridge (DIAGNOSTIC_TEST), Clauss Fibrinogen (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06261580?
This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06261580 being conducted?
This trial has 3 study locations across California, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06261580's enrollment target sits among peer trials
181 134th of 1090 higher than 957 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI